A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03238651 |
Recruitment Status :
Completed
First Posted : August 3, 2017
Last Update Posted : September 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lymphoma, Non-Hodgkin Lymphoma, Follicular, Marginal Zone | Drug: TAK-659 | Phase 1 |
The drug being tested in this study is called TAK-659. TAK-659 is being tested to treat people who have NHL or people who have relapsed and/or refractory NHL. This study will assess the safety, tolerability, PK, and preliminary efficacy of single-agent TAK-659 in East Asian participants with NHL.
The study will enroll approximately 33 to 47 participants, including at least 6 Japanese at RP2D dose level. Participants will be assigned to one of the following treatment groups:
Dose Escalation Part: TAK-659 Expansion Part: TAK-659 RP2D
This multi-center trial will be conducted in Japan and Republic of Korea. The maximum duration of participation in dose escalation part of the study is up to 12 months, unless in the opinion of the investigator and sponsor the participant would derive benefit from continued therapy beyond 12 months. In expansion part, participants who stop treatment for any other reason other than PD will continue to have PFS follow-up at the site every 2 months from the last dose of study drug up to 6 months or until PD. Participants will be followed 28 days after last dose of study drug or until the start of subsequent antineoplastic therapy, whichever occurs first, for a follow up assessment.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 17 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma |
Actual Study Start Date : | August 1, 2017 |
Actual Primary Completion Date : | August 17, 2020 |
Actual Study Completion Date : | August 17, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1
TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
|
Drug: TAK-659
TAK-659 Tablets. |
Experimental: Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1
TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
|
Drug: TAK-659
TAK-659 Tablets. |
Experimental: Expansion Part: TAK-659 MTD/RP2D
TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
|
Drug: TAK-659
TAK-659 Tablets. |
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 52 months ]
- Percentage of Participants With Grade 3 or Higher TEAEs [ Time Frame: Up to 52 months ]
- Percentage of Participants With Serious TEAEs [ Time Frame: Up to 52 months ]
- Dose Escalation Part: Percentage of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1 [ Time Frame: Up to dosing on Cycle 2 Day 1 ]
- Percentage of Participants Discontinuing Study Drug Because of TEAEs [ Time Frame: Up to 52 months ]
- Percentage of Participants With Clinically Significant Laboratory Values [ Time Frame: Up to 52 months ]
- Percentage of Participants With Clinically Significant Vital Sign Measurements [ Time Frame: Up to 52 months ]
- Cmax: Maximum Observed Plasma Concentration for TAK-659 on Cycle 1 Day 1 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 24 hours) ]
- Cmax: Maximum Observed Plasma Concentration for TAK-659 on Cycle 1 Day 7 or 15 [ Time Frame: Schedule A Day 15 and Schedule B Day 7: pre-dose and at multiple time points (up to 24 hours) ]
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659 on Cycle 1 Day 1 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 24 hours) ]
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659 on Cycle 1 Day 7 or 15 [ Time Frame: Schedule A Day 15 and Schedule B Day 7: pre-dose and at multiple time points (up to 24 hours) ]
- AUCτ: Area Under the Plasma Concentration-time Curve From Time During the Dosing Interval for TAK-659 on Cycle 1 Day 1 [ Time Frame: Day 1 pre-dose and at multiple time points (up to 24 hours) ]
- AUCτ: Area Under the Plasma Concentration-time Curve from Time During the Dosing Interval for TAK-659 on Cycle 1 Day 7 or 15 [ Time Frame: Schedule A Day 15 and Schedule B Day 7: pre-dose and at multiple time points (up to 24 hours) ]
- Renal Clearance (CLR) for TAK-659 on Cycle 1 Day 7 or 15 [ Time Frame: Schedule A Day 15 and Schedule B Day 7: pre-dose and at multiple time points (up to 24 hours) ]
- Expansion Part: Overall Response Rate (ORR) [ Time Frame: Up to 52 months ]The percentage of participants in the response-evaluable population of the expansion part who achieved either complete remission (CR) or partial remission (PR), as assessed by investigators, according to modified International Working Group (IWG) criteria for malignant lymphoma. CR is defined as disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
- Expansion Part: CR Rate [ Time Frame: Up to 52 months ]The percentage of participants in the response-evaluable population of the expansion part who achieved CR, as assessed by investigator, according to modified IWG criteria for malignant lymphoma. CR is defined as disappearance of all evidence of disease.
- Expansion Part: Duration of Response (DOR) [ Time Frame: Up to 52 months ]The time from first documentation of response (CR/PR) to the date of first documentation of PD/relapse, as assessed by investigator, according to modified IWG criteria for malignant lymphoma in the response-evaluable population of the expansion part. CR is defined as disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. Progressive disease (PD) is defined as any new lesion or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir.
- Expansion Part: Progression-free Survival (PFS) [ Time Frame: Up to 52 months ]The time from the date of first study drug administration to the day of first documented PD or death due to any cause, whichever occurs first, in the safety population of the expansion part, as assessed by the investigator, according to modified IWG criteria for malignant lymphoma. PD is defined as any new lesion or increase by >=50% of previously involved sites from nadir.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- To be enrolled to the dose escalation part, participants must have histologically or cytologically confirmed diagnosis of NHL for which no effective standard treatment is available.
-
To be enrolled in the expansion part, participants must meet the following criteria:
- Must have pathologically confirmed FL (Grade 1, 2, or 3A) or MZL.
- Relapsed and/or refractory to >=2 prior lines of chemotherapy based on standard of care that include at least 1 anti-CD20-based regimen, as well as alkylating agents (example cyclophosphamide or bendamustine).
- Participants must be ineligible for or refusal to hematopoietic stem cell transplant.
- If the participants have relapsed or progressed after achieving a response (defined as CR or PR), documented, investigator-assessed relapse or progression after the last treatment is required.
- Measurable disease per IWG 2007 criteria.
- Eastern Cooperative Oncology Group performance status score of 0 or 1.
- Life expectancy of longer than 3 months.
-
Adequate organ function, including the following:
- Bone marrow reserve: absolute neutrophil count >=1,000 per cubic millimeter (/mm^3), platelet count >=75,000/mm^3 (>=50,000/mm^3 for participants with bone marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL) (red blood cell [RBC] and platelet transfusion allowed >=14 days before assessment).
- Hepatic function: total bilirubin less than or equal to (<=) 1.5*the upper limit of the normal range (ULN); alanine aminotransferase and aspartate aminotransferase <=2.5*ULN.
- Renal function: creatinine clearance >=60 milliliter per minute (mL/min) either as estimated by the Cockcroft-Gault equation.
Exclusion Criteria:
- Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases as indicated by positive cytology from lumbar puncture or computed tomography (CT)/magnetic resonance imaging (MRI) by local assessment.
- Systemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agent; <=8 weeks for cell-based therapy or anti-tumor vaccine).
- Radiotherapy less than (<) 3 weeks before the first dose of study treatment. If prior radiotherapy occurred <4 to 6 weeks before the study start, as radiated lesions cannot be reliably assessed by fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET), nonradiated target lesions are required for eligibility.
- Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell transplant at any time.
- Any clinically significant comorbidities, such as uncontrolled pulmonary disease (example, severe chronic obstructive pulmonary disease with hypoxemia, interstitial lung disease, radiation induced lung injury), known impaired cardiac function or clinically significant cardiac disease, active CNS disease, or any other condition that could, in the opinion of the investigator, compromise the participant's safety and participation in the study per protocol.
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659.
- Use or consumption of any of the following substances:
Received medications, supplements, or food/beverages that are P-glycoprotein (P-gp) inhibitors or inducers or strong cytochrome P450 (CYP) 3A inhibitors or inducers within a certain time frame prior to the first dose of study drug. Depending on the substance, the washout period for P-gp inhibitors or inducers or strong CYP3A inhibitors or inducers will be either 7 days or 5 times the half-life (half-life is related to the time required for elimination from the body). The washout period for grapefruit containing food or beverages is 5 days.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03238651
Japan | |
NHO Nagoya Medical Center | |
Nagoya-shi, Aichi, Japan, 460-0001 | |
National Cancer Center Hospital | |
Chuo-ku, Tokyo, Japan, 104-0045 | |
Korea, Republic of | |
Seoul National University Hospital | |
Seoul, Korea, Republic of, 3080 | |
Samsung Medical Center | |
Seoul, Korea, Republic of, 6315 |
Study Director: | Medical Director Clinical Science | Millennium Pharmaceuticals, Inc. |
Responsible Party: | Millennium Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT03238651 |
Other Study ID Numbers: |
C34007 U1111-1186-6838 ( Registry Identifier: WHO ) |
First Posted: | August 3, 2017 Key Record Dates |
Last Update Posted: | September 2, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Drug therapy |
Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Follicular Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |